Weight Loss Vaccine
Metabolex, Sanofi-Aventis sign global license to develop GPR119 for type 2 diabetes treatment
Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.
Beauty Products Organic Garden Weight loss Vaccine Colloquial French
I am not really good with English but I find this really easygoing to interpret .